Clinical Trials

Phase 1 Active not recruiting

Hodgkin Disease, Lymphoma, Leukemia, Myelomonocytic, Chronic, Lymphoma, Large B-Cell, Diffuse

NCT03132454 2026-04-15

Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leukemia

32 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07409428 2026-04-01

A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 3 Recruiting

240 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04747912 2026-03-30

Study of Chemotherapy-Free Induction Regimen for Ph+ Acute Lymphoblastic Leukemia With Inotuzumab Ozogamicin (InO)

Phase 2 Suspended

25 enrolled

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06481735 2026-03-16

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06035757 2026-03-03

The Occurrence of Emergence Agitation in Pediatric Strabismus Surgery

Phase 4 Recruiting

76 enrolled

Emergence Delirium, Strabismus, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04752826 2026-02-18

MK-3475-D20

DermatologicGynecologicLymphoid

176 enrolled

Melanoma, Ovarian Neoplasms, Lymphoma, T-Cell

NCT06580301 2026-02-06

Study of YK012 in B-cell Acute Lymphoblastic Leukemia

46 enrolled

Burkitt Lymphoma

NCT06565689 2026-02-05

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012

Phase 1 Recruiting

48 enrolled

Phase 1/2 Not yet recruiting

Recurrence, Lymphoma, B-Cell

NCT07333469 2026-01-13

A Clinical Study of HX111 in Patients With Advanced Solid Tumor and Lymphoma

70 enrolled

Lymphoma

NCT06883526 2026-01-05

Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma

60 enrolled

Phase 1 Active not recruiting

Lymphoma

NCT05618327 2025-12-02

Phase I Clinical Study of JS203 in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

104 enrolled

Lymphoma, B-Cell

NCT06929624 2025-11-18

A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

280 enrolled

Phase 1/2 Active not recruiting

Lymphoma, Large B-Cell, Diffuse

NCT04697940 2025-09-19

Decitabine-primed Tandem CD19/CD20 CAR T Cells Treatment in r/r B-NHL

33 enrolled

Recurrence, Lymphoma, B-Cell

NCT07011056 2025-09-19

A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell Lymphoma

Phase 3 Recruiting

390 enrolled

Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05554939 2025-08-06

Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

Lymphoma, Non-Hodgkin, Recurrence

NCT07008885 2025-06-25

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07009002 2025-06-25

BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

LymphoidMyeloidOther hematologic neoplasm

Lymphoma, B-Cell

NCT01290302 2025-06-12

Blinded Cross-Over Bioequivalence (BE) Trial of Luitpold Azacitidine vs Vidaza

Phase 1 Completed

38 enrolled 14 charts

Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

NCT06601504 2025-06-06

Study of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

Phase 2 Active not recruiting

61 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06014073 2025-05-25

TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL

Lymphoma, Non-Hodgkin

NCT06323525 2025-05-25

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma